Irritable Bowel Syndrome Trial, Recruiting (NCT06749613)

Irritable Bowel Syndrome Trial, Recruiting NCT06749613 Sponsor: Attikon Hospital Condition: Irritable Bowel Syndrome

Printed from Voxsanity (voxsanity.com.au) — NCT06749613 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Irritable Bowel Syndrome

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are willing and able to give written consent to participate.
People who are available and able to attend throughout the entire study period.
People who were previously diagnosed with IBS (diarrhoea-type, mixed-type, or unclassified-type) and took part in an earlier clinical trial (NCT03997708), where they responded well to a specific diet (Mediterranean Diet Adjusted to Low FODMAP), but whose symptoms have since returned with a symptom score above 175 on the IBS symptom severity scale.
People who were assigned to the Mediterranean Diet Adjusted to Low FODMAP group in the earlier study but were unable to stick to that diet.

Who may not be able to join:

People who did not take part in the earlier clinical trial (NCT03997708).
People who were assigned to the NICE diet group (rather than the Mediterranean Diet Adjusted to Low FODMAP group) in the earlier trial.
People whose current IBS symptom severity score is 175 or below (confirm with trial site what scoring method is used).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 6942917860

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06749613

Sponsor: Attikon Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Irritable Bowel Syndrome

Trial contact: 6942917860

More information: https://clinicaltrials.gov/study/NCT06749613

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are willing and able to give written consent to participate.
People who are available and able to attend throughout the entire study period.
People who were previously diagnosed with IBS (diarrhoea-type, mixed-type, or unclassified-type) and took part in an earlier clinical trial (NCT03997708), where they responded well to a specific diet (Mediterranean Diet Adjusted to Low FODMAP), but whose symptoms have since returned with a symptom score above 175 on the IBS symptom severity scale.
People who were assigned to the Mediterranean Diet Adjusted to Low FODMAP group in the earlier study but were unable to stick to that diet.

Who may not be able to join:

People who did not take part in the earlier clinical trial (NCT03997708).
People who were assigned to the NICE diet group (rather than the Mediterranean Diet Adjusted to Low FODMAP group) in the earlier trial.
People whose current IBS symptom severity score is 175 or below (confirm with trial site what scoring method is used).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Attikon Hospital

Registry

ClinicalTrials.gov

Start date

10 December 2024

Est. completion

10 October 2025

Where this trial is recruiting

🇬🇷 Greece

Primary endpoints

Changes in IBS-SSS from baseline to follow-up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov